Comprehensive Analysis of Predictive Factors for Rapid Angiographic Stenotic Progression and Restenosis Risk in Coronary Artery Disease Patients Underwent Percutaneous Coronary Intervention with Drug-eluting Stents Implantation

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2018 Sep 18

PMID 30221497

Citations 13

Authors

Yanqiang Wu

Xianghua Fu

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to explore the correlation of baseline, procedural, and postprocedure characteristics with the risk of rapid angiographic stenotic progression (RASP) and restenosis in coronary artery disease (CAD) patients after percutaneous coronary intervention (PCI) with drug-eluting stents implantation.

Methods: Two hundred fourteen CAD patients underwent PCI with drug-eluting stents implantation were consecutively enrolled. Baseline, procedural, and postprocedure characteristics of patients were collected for analysis. Coronary angiography was performed to evaluate coronary stenosis before PCI and at 12 months after PCI. RASP of nontarget lesions and restenosis of stent-implanted target lesions were then assessed.

Results: 37.8% CAD patients occurred RASP at 12 months after PCI and compared to non-RASP group, RASP group presented with increased diabetes mellitus (DM) complication, higher concentration of serum uric acid (SUA), cardiac troponin I, N-terminal probrain natriuretic peptide, and high sensitive C-reactive protein (hs-CRP) as well as elevated occurrence of multivessel artery lesions. In addition, DM, SUA, hs-CRP, and multivessel artery lesions independently predicted high RASP risk. For restenosis, 21.0% patients occurred restenosis at 12 months after PCI, and patients in restenosis group presented with increased hypertension and DM occurrence, higher concentrations of SUA, LDL-C, and hs-CRP, as well as longer target lesion and length of stent in surgery compared to nonrestenosis group. Also, DM, SUA, LDL-C, hs-CRP, and length of target lesion independently predicted increased restenosis risk.

Conclusion: Diabetes mellitus, SUA, and hs-CRP are potential predictive factors for increased risk of both RASP and restenosis in CAD patients underwent PCI and drug-eluting stents implantation.

Citing Articles

Unraveling the rapid progression of non-target lesions: risk factors and the therapeutic potential of PCSK9 inhibitors in post-PCI patients.

Mei J, Fu X, Liu Z, Zhang L, Geng Z, Xie W BMC Cardiovasc Disord. 2024; 24(1):499.

PMID: 39294556 PMC: 11409538. DOI: 10.1186/s12872-024-04186-2.

Effect of Serum IL-6 Levels on the Progression of Non-Target Lesions in Patients after Coronary Stenting.

Sha X, Wang W, Qiu J, Wang R Rev Cardiovasc Med. 2024; 25(7):234.

PMID: 39139413 PMC: 11317311. DOI: 10.31083/j.rcm2507234.

Serum 5'-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease.

Aimaitijiang M, Wu T, Zheng Y, Hou X, Yang H, Yang Y Rev Cardiovasc Med. 2024; 25(1):17.

PMID: 39077643 PMC: 11262354. DOI: 10.31083/j.rcm2501017.

Serum Globulin to Albumin Ratio as a Novel Predictor of Adverse Clinical Outcomes in Coronary Artery Disease Patients Who Underwent PCI.

Wang S, Wu T, Zheng Y, Hou X, Yang H, Yang Y Rev Cardiovasc Med. 2024; 24(10):278.

PMID: 39077558 PMC: 11273180. DOI: 10.31083/j.rcm2410278.

Biomarkers Associated with Immune Checkpoint, N6-Methyladenosine, and Ferroptosis in Patients with Restenosis.

Tong X, Zhao X, Dang X, Kou Y, Kou J J Inflamm Res. 2023; 16:407-420.

PMID: 36755968 PMC: 9901443. DOI: 10.2147/JIR.S392036.

References

Kornowski R, Hong M, Tio F, Bramwell O, Wu H, Leon M . In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998; 31(1):224-30. DOI: 10.1016/s0735-1097(97)00450-6. View

Sukhija R, Aronow W, Sureddi R, Aleti S, Molavi B, Sachdeva R . Predictors of in-stent restenosis and patient outcome after percutaneous coronary intervention in patients with diabetes mellitus. Am J Cardiol. 2007; 100(5):777-80. DOI: 10.1016/j.amjcard.2007.03.097. View

Kim S, Guevara J, Kim K, Choi H, Heitjan D, Albert D . Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010; 62(2):170-80. PMC: 3156692. DOI: 10.1002/acr.20065. View

Wu Y, Fu X . Comprehensive analysis of predictive factors for rapid angiographic stenotic progression and restenosis risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents implantation. J Clin Lab Anal. 2018; 33(2):e22666. PMC: 6818547. DOI: 10.1002/jcla.22666. View

Lubrano V, Balzan S . Consolidated and emerging inflammatory markers in coronary artery disease. World J Exp Med. 2015; 5(1):21-32. PMC: 4308529. DOI: 10.5493/wjem.v5.i1.21. View

Hsieh I, Chen C, Hsieh M, Yang C, Chen D, Chang S . Prognostic Impact of 9-Month High-Sensitivity C-Reactive Protein Levels on Long-Term Clinical Outcomes and In-Stent Restenosis in Patients at 9 Months after Drug-Eluting Stent Implantation. PLoS One. 2015; 10(9):e0138512. PMC: 4583430. DOI: 10.1371/journal.pone.0138512. View

Zhao L, Zhu W, Zhang X, He D, Guo C . Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis. BMC Cardiovasc Disord. 2017; 17(1):16. PMC: 5217259. DOI: 10.1186/s12872-016-0445-6. View

Gogo Jr P, Schneider D, Watkins M, Terrien E, Sobel B, Dauerman H . Systemic inflammation after drug-eluting stent placement. J Thromb Thrombolysis. 2005; 19(2):87-92. DOI: 10.1007/s11239-005-1378-6. View

Trikalinos T, Alsheikh-Ali A, Tatsioni A, Nallamothu B, Kent D . Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet. 2009; 373(9667):911-8. PMC: 2967219. DOI: 10.1016/S0140-6736(09)60319-6. View

10.

Zairis M, Manousakis S, Stefanidis A, Vitalis D, Tsanis E, Hadjigeorgiou S . C-reactive protein and rapidly progressive coronary artery disease--is there any relation?. Clin Cardiol. 2003; 26(2):85-90. PMC: 6654678. DOI: 10.1002/clc.4960260208. View

11.

Assimes T, Roberts R . Genetics: Implications for Prevention and Management of Coronary Artery Disease. J Am Coll Cardiol. 2016; 68(25):2797-2818. DOI: 10.1016/j.jacc.2016.10.039. View

12.

Aoki J, Kirtane A, Leon M, Dangas G . Coronary artery aneurysms after drug-eluting stent implantation. JACC Cardiovasc Interv. 2009; 1(1):14-21. DOI: 10.1016/j.jcin.2007.10.004. View

13.

Galkina E, Ley K . Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol. 2009; 27:165-97. PMC: 2734407. DOI: 10.1146/annurev.immunol.021908.132620. View

14.

Wang J, Qin Z, Wang Z, Shi D, Liu Y, Zhao Y . New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent. J Geriatr Cardiol. 2018; 15(2):137-145. PMC: 5895953. DOI: 10.11909/j.issn.1671-5411.2018.02.011. View

15.

Imai K, Okura H, Kume T, Yamada R, Miyamoto Y, Kawamoto T . C-reactive protein predicts non-target lesion revascularization and cardiac events following percutaneous coronary intervention in patients with angina pectoris. J Cardiol. 2009; 53(3):388-95. DOI: 10.1016/j.jjcc.2009.01.005. View

16.

Watanabe Y, Takagi K, Naganuma T, Kawamoto H, Fujino Y, Ishiguro H . Independent predictors of in-stent restenosis after drug-eluting stent implantation for ostial right coronary artery lesions. Int J Cardiol. 2017; 240:108-113. DOI: 10.1016/j.ijcard.2017.04.083. View

17.

Her A, Shin E . Current Management of In-Stent Restenosis. Korean Circ J. 2018; 48(5):337-349. PMC: 5940640. DOI: 10.4070/kcj.2018.0103. View

18.

Glass C, Witztum J . Atherosclerosis. the road ahead. Cell. 2001; 104(4):503-16. DOI: 10.1016/s0092-8674(01)00238-0. View

19.

Gaubert M, Marlinge M, Alessandrini M, Laine M, Bonello L, Fromonot J . Uric acid levels are associated with endothelial dysfunction and severity of coronary atherosclerosis during a first episode of acute coronary syndrome. Purinergic Signal. 2018; 14(2):191-199. PMC: 5940631. DOI: 10.1007/s11302-018-9604-9. View

20.

Xu Y, Li J, Xu B, Zhu C, Yang Y, Chen J . Increased plasma C-reactive protein level predicts rapid progression of non-target atherosclerotic lesions in patients with stable angina after stenting. Chin Med J (Engl). 2011; 124(19):3022-9. View